Ovarian cancer trials in South Korea

In South Korea 65 Also abroad 794

65 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Where
Busan, Seoul
Age
18 years and over
People
172 worldwide
Run by
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT04516447 · EU 2025-524868-38-00
Phase 3Taking people
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Where
Daegu, Goyang-si, Seoul
Age
18 years and over
People
420 worldwide
Run by
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT07546500
No phaseTaking people
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Where
Dalseo-gu, Gwangmyeong, Seongnam, Seoul
Age
35 years to 50 years
People
1,956 worldwide
Run by
NRG Oncology
See details and how to joinNCT04251052
Phase 2Taking people
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Where
Daegu, Gyeonggi-do, Incheon, Seongnam-si, Seoul
Age
18 years and over
People
397 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06787612 · EU 2024-517806-27-00
Phase 3Taking people
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Where
Busan, Daegu, Goyang-si, Gyeonggi-do, Seongnam-si, Seoul, Yangsan
Age
18 years and over
People
950 worldwide
Run by
AstraZeneca
See details and how to joinNCT07851025 · EU 2026-526895-22-00
Phase 1Taking people
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Where
Gwangmyeong, Seoul
Age
19 years and over
People
238 worldwide
Run by
NiKang Therapeutics, Inc.
See details and how to joinNCT06586957
Phase 3Taking people
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Where
Seoul
Age
18 years and over
People
802 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07776691 · EU 2025-524592-22-00
Phase 1/2Taking people
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Where
Seoul
Age
18 years and over
People
952 worldwide
Run by
Genmab
See details and how to joinNCT05579366
Phase 3Taking people
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Where
Seoul
Age
18 years to 60 years
People
3,960 worldwide
Run by
NRG Oncology
See details and how to joinNCT05879926
Phase 1Taking people
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Where
Goyang-si Gyeonggi-do
Age
18 years and over
People
575 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00
Phase 1Taking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Seoul
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Phase 2Taking people
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Where
Gangnam-Gu, Guro-gu, Hwasun-Eup, Jongno-gu, Seodaemun-gu, Seoul, Suwon
Age
18 years and over
People
200 worldwide
Run by
Jazz Pharmaceuticals
See details and how to joinNCT06695845 · EU 2024-516551-41-00
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Jongno -Gu, Seoul
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 3Taking people
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Where
Daegu, Goyang-si, Seongnam, Seoul, Suwon
Age
18 years and over
People
1,630 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00
Phase 3Taking people
Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]
Where
Seoul
Age
18 years and over
People
720 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07694427 · EU 2025-523365-13-00
Phase 3Taking people
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Where
Seongnam, Seoul
Age
18 years and over
People
270 worldwide
Run by
Verastem, Inc.
See details and how to joinNCT06072781 · EU 2023-508204-38-00
Phase 2Taking people
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Where
Goyang-si, Seoul
Age
18 years and over
People
310 worldwide
Run by
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT05128825 · EU 2022-502983-19-00
Phase 1/2Taking people
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
Where
Goyang-si, Seoul
Age
18 years and over
People
605 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06843447 · EU 2024-514674-47-00
Phase 3Taking people
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Where
Daegu, Goyang-si, Seongnam-si, Seoul
Age
18 years and over
People
582 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06819007 · EU 2024-516982-35-00
Phase 2/3Taking people
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Where
Goyang-si, Seongnam, Seongnam-si, Seoul
Age
18 years and over
People
860 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06161025 · EU 2023-507914-28-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Daegu, Gyeonggi-do, Seongnam, Seoul
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 3Taking people
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
Where
Goyang-si, Seoul
Age
18 years and over
People
600 worldwide
Run by
AstraZeneca
See details and how to joinNCT07816666 · EU 2026-526776-23-00
Phase 3Taking people
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Where
Ansan-si, Changwon-Si, Daegu, Goyang-si, Seongnam-si, Seoul
Age
18 years and over
People
466 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07214779 · EU 2025-522748-42-00
Phase 3Taking people
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
Where
Gyeonggi-do, Seoul, Suwon Kyunggi-do
Age
18 years and over
People
450 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07286266 · EU 2025-523361-25-00
Phase 1Taking people
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Where
Busan, Cheongju-si, Jinju, Seoul
Age
18 years and over
People
325 worldwide
Run by
AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00